Samarth Kulkarni

Chairman and CEO, CRISPR Therapeutics

About

Samarth Kulkarni is the chairman and chief executive officer of CRISPR Therapeutics, a gene-editing company whose Casgevy therapy is reported in its quarterly results. CRISPR's third-quarter 2026 results release, dated November 2, 2026, quotes him as chairman and CEO. The company's 2026 proxy statement says he has been CEO since December 2017, a director since June 2018 and chairman since September 2023. He previously served as president and chief business officer of the company.

Kulkarni received a Ph.D. in bioengineering and nanotechnology from the University of Washington and a B.Tech. from the Indian Institute of Technology, according to the proxy statement. Before CRISPR he was at McKinsey & Company from 2006 to 2015, and his most recent title there was partner in the pharmaceuticals and biotechnology practice. Other pharmaceutical leaders with pages on Whoo include Reshma Kewalramani of Vertex Pharmaceuticals and Yvonne Greenstreet of Alnylam.

Whoo compiled this page from public sources: CRISPR Therapeutics third-quarter 2026 results release (via Finviz), CRISPR Therapeutics 2026 proxy statement (SEC), Aspen Ideas. It is not affiliated with or endorsed by Samarth Kulkarni. Are you Samarth Kulkarni? Claim this page, or write to [email protected] to correct or remove it. Last updated: 2026-11-18.

Want a page like this? Create yours from your résumé.

Experience

Chairman and Chief Executive Officer — CRISPR Therapeutics


December 2017 – Present

  • Board member since June 2018

  • Chairman since September 2023
  • President and Chief Business Officer — CRISPR Therapeutics

    Partner, Pharmaceuticals and Biotechnology practice — McKinsey & Company


    2006 – 2015

  • Held various titles; partner was the most recent

Education

Ph.D. in Bioengineering and Nanotechnology — University of Washington

B.Tech. — Indian Institute of Technology


Projects